Ralimetinib dimesylate

Cat. No.: OB0125LY-095

Appearance: Solid

Purity: 99.3%

Identity: Confirmed by NMR and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Ralimetinib dimesylate is a small molecule compound that belongs to the MAPK inhibitor and works mainly by inhibiting specific signaling pathways.

Synonym: 862507-23-1; Ralimetinib Mesylate; 5-(2-(Tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate; 5-(2-(Tert-Butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate; 5-[2-Tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate; 5-(2-(Tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-3H-imidazo (4,5-b)pyridin-2-amine methanesulfonate; 5-(2-Tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate

CAS No.: 862507-23-1

Compound CID: 11570805

Formula: C₂₄H₂₉FN₆·2CH₄O₃S

Formula Weight: 612.74

Specification

Targets & IC50: p38α: 7 nM

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Ralimetinib dimesylate has strong anti-tumor activity and can be used in studies of non-small cell lung cancer and other solid tumor diseases.